<i>ARID1A</i> ‐deficient cells require HDAC6 for progression of endometrial carcinoma-Reference-Cited by-同舟云学术

ARID1A ‐deficient cells require HDAC6 for progression of endometrial carcinoma

Published:2022-03-02 Issue:11 Volume:16 Page:2235-2259
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Megino‐Luque Cristina¹²,Sisó Pol³,Mota‐Martorell Natalia⁴,Navaridas Raúl¹,Rosa Inés³,Urdanibia Izaskun¹,Albertí‐Valls Manel¹²,Santacana Maria²⁵,Pinyol Miquel¹⁶,Bonifaci Núria²⁷,Macià Anna⁸,Llobet‐Navas David²⁷^ORCID,Gatius Sònia¹²⁶,Matias‐Guiu Xavier¹²⁶⁹,Eritja Núria²³^ORCID

Affiliation:

1. Oncologic Pathology Group Department of Basic Medical Sciences Biomedical Research Institute of Lleida (IRBLleida) University of Lleida Spain

2. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid Spain

3. Oncologic Pathology Group Department of Medicine Biomedical Research Institute of Lleida (IRBLleida) University of Lleida Spain

4. Metabolic Physiopathology Group Department of Experimental Medicine Biomedical Research Institute of Lleida (IRBLleida) University of Lleida Spain

5. Scientific and Technical Service of Immunohistochemistry Biomedical Research Institute of Lleida (IRBLleida) Hospital Universitari Arnau de Vilanova Lleida Spain

6. Department of Pathology Hospital Universitari Arnau de Vilanova Lleida Spain

7. Molecular Mechanisms and Experimental Therapy in Oncology‐Oncobell Program Bellvitge Biomedical Research Institute (IDIBELL) Barcelona Spain

8. Oncologic Pathology Group Department of Experimental Medicine Biomedical Research Institute of Lleida (IRBLleida) University of Lleida Spain

9. Department of Pathology Hospital Universitari de Bellvitge IDIBELL University of Barcelona Spain

Funder

Fundación Científica Asociación Española Contra el Cáncer

Instituto de Salud Carlos III

Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya

Fundación Dexeus Mujer

Publisher

Wiley

Subject